CDMO Indena will be participating at DCAT Week 2026 (March 23-26, 2026, New York).
In an announcement, the company said that it would highlight its "expanded capabilities in Highly Potent Active Pharmaceutical Ingredients (HPAPIs), Antibody-Drug Conjugates (ADCs) and advancements in Peptide Drug Conjugates (PDCs)" at the show.
Indena currently produces ten commercial and 13 clinical-phase HPAPIs, supported by a robust R&D team and a dedicated CDMO division that delivers customised, end-to-end solutions—from early clinical development to commercial supply.
The brand integrates advanced technologies—semisynthesis, chemical synthesis, microbial fermentation and plant extraction—providing full flexibility in the processing of complex molecules.
Indena also highlights the growing landscape of oncology New Chemical Entities (NCEs), ADCs and personalised medicine approaches, which have driven increasing demand for specialised CDMO services. The company says that it is well-placed to support oncology-focused innovation due to its long-standing expertise in high-potency compounds.
The firm said that it is also pursuing a strategic interest in advancing Peptide Drug Conjugate (PDC) through collaborative models.
"Our continuous investments across our global operations, from advanced GMP lines and high-containment laboratories to expanded precision fermentation capacity, underscore Indena's unwavering commitment to innovation and safety in HPAPI manufacturing, achieving OELs as low as 1 ng/m3," said Bernard Vianes, Global CDMO Director at Indena.
Moreover, we're working to complement our core strengths and expand our offering in the rapidly evolving landscape of targeted therapies, providing clients with increasingly comprehensive and highly advanced solutions for ADCs and PDCs.
Stefano Togni, Chief Commercial Officer at Indena, added: "In today's dynamic pharmaceutical market, especially for specialised oncology and high-potency compounds, clients demand more than just capacity; they seek integrated expertise, flexibility and unwavering reliability."
"Indena delivers this through our comprehensive, end-to-end solutions, continuously enhanced by strategic investments and our deep knowledge of complex molecules."
Our continuous investment in advanced technologies and our deep expertise in complex molecules ensures we deliver the scientific depth and operational excellence our partners need to bring innovative medicines to patients faster.
The company added that it is particularly focused on empowering small and mid-sized pharmaceutical and biotech companies, acting as a strategic CDMO partner by offering agile, high-quality development and manufacturing solutions specifically tailored to their project lifecycle.